Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ophthalmologic examinations Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

The K-Map Study, Global Prevalence of KC

NCT03115710
View directory record Official record
Conditions
Keratoconus
Interventions
Rotating Scheimpflug camera (Pentacam HR)
Diagnostic Test
Lead sponsor
University Hospital, Geneva
Other
Eligibility
6 Years to 23 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You

NCT04227197
View directory record Official record
Conditions
Down Syndrome
Interventions
Down Syndrome Clinic to You (DSC2U)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year and older
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 20, 2026, 5:48 PM EDT
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
View directory record Official record
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mirapex, Requip
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 20, 2026, 5:48 PM EDT
Completed No phase listed Observational Results available

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

NCT03868254
View directory record Official record
Conditions
Glaucoma
Interventions
XEN Group, Phacoemulsification
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 20, 2026, 5:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 20, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analyzing Retinal Microanatomy in ROP

NCT02887157
View directory record Official record
Conditions
Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
Interventions
Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection
Device · Other
Lead sponsor
Duke University
Other
Eligibility
30 Weeks and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Ozurdex for the Control of Uveitis

NCT02049476
View directory record Official record
Conditions
Uveitis, Intermediate, Uveitis, Posterior
Interventions
Dexamethasone pellet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 20, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

NCT06841575
View directory record Official record
Conditions
Eye Diseases, Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions
Auto-aligned OCT
Device
Lead sponsor
Duke University
Other
Eligibility
1 Month and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 5:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Enhanced Housing Photoscreeners 2WIN and GoCheckKids Compared in Burma and Alaska

NCT04068129
View directory record Official record
Conditions
Amblyopia, Anisometropia
Interventions
photoscreen
Device
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
6 Months to 40 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

NCT01323348
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
Diabetes Education
Behavioral
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Loma Linda, California • Santa Barbara, California • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 20, 2026, 5:48 PM EDT
Withdrawn No phase listed Observational

Assessment of COVID-19 in Tearfilm

NCT04579458
View directory record Official record
Conditions
Covid19, Ophthalmopathy, Eye Diseases
Interventions
Collection of tears and saliva.
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 20, 2026, 5:48 PM EDT
Not yet recruiting No phase listed Observational

Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)

NCT07623837
View directory record Official record
Conditions
Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
Interventions
Glandy EOM (AI-based quantitative eye movement analysis software)
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department

NCT03106025
View directory record Official record
Conditions
Retinal Detachment
Interventions
Ultrasound, Ophthalmology Assessment
Device · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 20, 2026, 5:48 PM EDT
Completed No phase listed Observational

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

NCT01863238
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ophthalmologic examinations, Ivacaftor Exposed
Other · Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 20, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632
View directory record Official record
Conditions
Optic Nerve Diseases
Interventions
Zyvox - linezolid, Matched control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jonesboro, Arkansas • West Palm Beach, Florida • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 20, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

NCT02658435
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 150 mg, Matched placebo 150mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Glendale, California • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 20, 2026, 5:48 PM EDT
Terminated Not applicable Interventional

Use of Sucrose to Relieve Pain During Eye Exams in Infants

NCT00161694
View directory record Official record
Conditions
Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions
sucrose solution
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
5 Weeks and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 20, 2026, 5:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939
View directory record Official record
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Interventions
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
Drug
Lead sponsor
Ocugen
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 5:48 PM EDT